Lexicon Pharmaceuticals (LXRX) Completes Offering with Gross Proceeds of $161 Million
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Join SI Premium – FREE
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has completed its previously announced rights offering pursuant to an effective shelf registration statement. Under the rights offering, an aggregate of 142,492,883 shares of common stock will be issued at a subscription price of $1.13 per share, resulting in aggregate gross proceeds to Lexicon of approximately $161 million.
Lexicon conducted the rights offering at the election of two of its largest stockholders, Invus, L.P. and Invus C.V., pursuant to their contractual rights to require Lexicon to initiate a pro rata rights offering to its stockholders. Invus, L.P. and its affiliates subscribed for an aggregate of 115,044,247 shares of common stock in the rights offering and will beneficially own approximately 58.3% of Lexicon's outstanding common stock following completion of the rights offering.
Lexicon conducted the rights offering at the election of two of its largest stockholders, Invus, L.P. and Invus C.V., pursuant to their contractual rights to require Lexicon to initiate a pro rata rights offering to its stockholders. Invus, L.P. and its affiliates subscribed for an aggregate of 115,044,247 shares of common stock in the rights offering and will beneficially own approximately 58.3% of Lexicon's outstanding common stock following completion of the rights offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
- ESS Tech closes $3.2M stock offering at $0.50 per share
- MAIA Biotechnology (MAIA) files $150M mixed shelf
Create E-mail Alert Related Categories
Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
